(2S)-Isopropyl 2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate fumarate

Catalog No. :
ACJCXZ250
CAS No. :
390409-17-3
Molecular Formula :
C25H33N6O9P
Molecular Weight :
592.55

IUPAC Name:isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate fumarate

(2S)-Isopropyl 2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate fumarate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2S)-Isopropyl 2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate fumarate
IUPAC Nameisopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate fumarate
Molecular FormulaC25H33N6O9P
Molecular Weight592.55
SMILESNC1=C2C(N(C[C@@H](C)OCP(OC3=CC=CC=C3)(N[C@@H](C)C(OC(C)C)=O)=O)C=N2)=NC=N1.OC(/C=C/C(O)=O)=O
InChI KeyMEJAFWXKUKMUIR-WIUYAKJJSA-N
Synonym[2H6]-Tenofovir alafenamide fumarate;GS-7171 fumarate;2H6]-GS-7171 fumarate;GS-7171 fumarate salt;D5-Tenofovir Alafenamide Fumarate (diastereomers);D6-GS-7171 fumarate
CAS No.390409-17-3

Synthetic Route by SureRoute

1. ACJCXZ250 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKQTI475 route compound structure diagram
    ACKQTI47562062-65-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJCXZ250 route product structure diagram
    ACJCXZ250390409-17-3
Inquiry

2. ACJCXZ250 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKIQW295 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJCXZ250 route product structure diagram
    ACJCXZ250390409-17-3
Inquiry

Comments (0)